---
document_datetime: 2025-12-02 05:32:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/defitelio.html
document_name: defitelio.html
version: success
processing_time: 0.1178187
conversion_datetime: 2025-12-27 09:50:21.642382
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Defitelio

[RSS](/en/individual-human-medicine.xml/65900)

##### Authorised

This medicine is authorised for use in the European Union

defibrotide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Defitelio](#news-on)
- [More information on Defitelio](#more-information-on-defitelio-38667)
- [More information on Defitelio](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Defitelio is a medicine used to treat severe veno-occlusive disease (VOD) in patients undergoing haematopoietic (blood) stem cell transplantation. VOD is a condition in which the veins in the liver become blocked and stop the liver working properly. Defitelio is used in adults and in children from one month of age.

Defitelio contains the active substance defibrotide.

VOD is rare, and Defitelio was designated an 'orphan medicine' (a medicine used in rare diseases) on 29 July 2004.

Expand section

Collapse section

## How is Defitelio used?

Defitelio can only be obtained with a prescription and it must be prescribed and given by a doctor experienced in the management of complications of blood stem cell transplantation. It is given by infusion (drip) into a vein over 2 hours 4 times a day. The dose depends on the patient's bodyweight. Treatment should last for at least 3 weeks and continue until the patient no longer has symptoms. For more information about using Defitelio, see the package leaflet or contact your doctor or pharmacist.

## How does Defitelio work?

VOD is usually a complication resulting from a treatment known as 'myeloablative chemotherapy' given before blood stem cell transplantation. Myeloablative chemotherapy is used to clear the patient's bone marrow of cells before receiving healthy stem cells. The medicines used for this treatment can damage the lining of the blood vessels in the liver, leading to the formation of clots and obstruction of the vessels seen in VOD.

The active substance in Defitelio, defibrotide, works by increasing the breakdown of clots in the blood. In addition, defibrotide may protect the cells that line blood vessels.

## What benefits of Defitelio have been shown in studies?

Severe VOD has a high mortality rate of 75% or higher. In one main study involving 102 patients with severe VOD following blood stem cell transplantation, Defitelio was compared with past records of patients who had received standard supportive care. Defitelio lowered the mortality rate to 62% at 100 days after transplantation, and 24% of patients had no symptoms of severe VOD after 100 days.

Benefits of Defitelio were also seen in data from a United States patient registry (information about patients collected in a standard way), where patients with severe VOD after blood stem cell transplantation who received Defitelio plus standard care had better outcomes than those given standard care alone, including a higher 100-day survival rate (39% versus 31%) and a higher proportion of patients whose VOD resolved (51% versus 29%).

## What are the risks associated with Defitelio?

The most common side effects with Defitelio are hypotension (low blood pressure) and bleeding. For the full list of side effects of Defitelio, see the package leaflet.

Defitelio must not be used together with other medicines that break down blood clots. For the full list of restrictions, see the package leaflet.

## Why is Defitelio authorised in the EU?

The European Medicines Agency decided that Defitelio's benefits are greater than its risks and it can be authorised for use in the EU. Defitelio had been shown to improve survival in patients with severe VOD. Although it was not possible to conduct a study directly comparing Defitelio with placebo (dummy treatment), the company had provided sufficient data to show that patients treated with the medicine had improved chances of survival. The side effects seen, such as bleeding, were considered manageable and it was not possible to determine with certainty whether they were caused by Defitelio.

Defitelio has been authorised under 'exceptional circumstances'. This is because it has not been possible to obtain complete information about Defitelio due to the rarity of the disease. Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Defitelio

Since Defitelio has been authorised under exceptional circumstances, the company that markets the medicine is required to provide results of an ongoing study on safety of the medicine when used for prevention of VOD in adults and children undergoing hematopoietic stem cell transplantation. The company will also analyse data on transplant outcomes in VOD patients who have and have not been treated with Defitelio.

## What measures are being taken to ensure the safe and effective use of Defitelio?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Defitelio have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Defitelio are continuously monitored. Side effects reported with Defitelio are carefully evaluated and any necessary action taken to protect patients.

## Other information about Defitelio

Defitelio received a marketing authorisation valid throughout the European Union on 18 October 2013.

Defitelio : EPAR - Medicine overview

Reference Number: EMA/300180/2018

English (EN) (116.94 KB - PDF)

**First published:** 25/10/2013

**Last updated:** 19/11/2019

[View](/en/documents/overview/defitelio-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-893)

български (BG) (141.8 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/bg/documents/overview/defitelio-epar-medicine-overview_bg.pdf)

español (ES) (116.92 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/es/documents/overview/defitelio-epar-medicine-overview_es.pdf)

čeština (CS) (139.28 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/cs/documents/overview/defitelio-epar-medicine-overview_cs.pdf)

dansk (DA) (115.16 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/da/documents/overview/defitelio-epar-medicine-overview_da.pdf)

Deutsch (DE) (119.25 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/de/documents/overview/defitelio-epar-medicine-overview_de.pdf)

eesti keel (ET) (112.89 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/et/documents/overview/defitelio-epar-medicine-overview_et.pdf)

ελληνικά (EL) (138.46 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/el/documents/overview/defitelio-epar-medicine-overview_el.pdf)

français (FR) (118.3 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/fr/documents/overview/defitelio-epar-medicine-overview_fr.pdf)

hrvatski (HR) (138.5 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/hr/documents/overview/defitelio-epar-medicine-overview_hr.pdf)

italiano (IT) (114.72 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/it/documents/overview/defitelio-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (153.46 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/lv/documents/overview/defitelio-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (139.31 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/lt/documents/overview/defitelio-epar-medicine-overview_lt.pdf)

magyar (HU) (138.76 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/hu/documents/overview/defitelio-epar-medicine-overview_hu.pdf)

Malti (MT) (140.22 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/mt/documents/overview/defitelio-epar-medicine-overview_mt.pdf)

Nederlands (NL) (114.33 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/nl/documents/overview/defitelio-epar-medicine-overview_nl.pdf)

polski (PL) (142.15 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/pl/documents/overview/defitelio-epar-medicine-overview_pl.pdf)

português (PT) (117.15 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/pt/documents/overview/defitelio-epar-medicine-overview_pt.pdf)

română (RO) (137.31 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/ro/documents/overview/defitelio-epar-medicine-overview_ro.pdf)

slovenčina (SK) (138.15 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/sk/documents/overview/defitelio-epar-medicine-overview_sk.pdf)

slovenščina (SL) (137.25 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/sl/documents/overview/defitelio-epar-medicine-overview_sl.pdf)

Suomi (FI) (113.79 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/fi/documents/overview/defitelio-epar-medicine-overview_fi.pdf)

svenska (SV) (114.45 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

19/11/2019

[View](/sv/documents/overview/defitelio-epar-medicine-overview_sv.pdf)

Defitelio : EPAR - Risk-management-plan summary

English (EN) (166.67 KB - PDF)

**First published:** 19/11/2019

**Last updated:** 15/06/2023

[View](/en/documents/rmp-summary/defitelio-epar-risk-management-plan-summary_en.pdf)

## Product information

Defitelio : EPAR - Product Information

English (EN) (345.44 KB - PDF)

**First published:** 25/10/2013

**Last updated:** 20/12/2023

[View](/en/documents/product-information/defitelio-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-911)

български (BG) (440.35 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/bg/documents/product-information/defitelio-epar-product-information_bg.pdf)

español (ES) (309.69 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/es/documents/product-information/defitelio-epar-product-information_es.pdf)

čeština (CS) (383.92 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/cs/documents/product-information/defitelio-epar-product-information_cs.pdf)

dansk (DA) (313.35 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/da/documents/product-information/defitelio-epar-product-information_da.pdf)

Deutsch (DE) (328.91 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/de/documents/product-information/defitelio-epar-product-information_de.pdf)

eesti keel (ET) (330.79 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/et/documents/product-information/defitelio-epar-product-information_et.pdf)

ελληνικά (EL) (445.97 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/el/documents/product-information/defitelio-epar-product-information_el.pdf)

français (FR) (337.57 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/fr/documents/product-information/defitelio-epar-product-information_fr.pdf)

hrvatski (HR) (390.95 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/hr/documents/product-information/defitelio-epar-product-information_hr.pdf)

íslenska (IS) (320.8 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/is/documents/product-information/defitelio-epar-product-information_is.pdf)

italiano (IT) (315.51 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/it/documents/product-information/defitelio-epar-product-information_it.pdf)

latviešu valoda (LV) (406.07 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/lv/documents/product-information/defitelio-epar-product-information_lv.pdf)

lietuvių kalba (LT) (383.18 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/lt/documents/product-information/defitelio-epar-product-information_lt.pdf)

magyar (HU) (398.76 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/hu/documents/product-information/defitelio-epar-product-information_hu.pdf)

Malti (MT) (414.09 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/mt/documents/product-information/defitelio-epar-product-information_mt.pdf)

Nederlands (NL) (357.88 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/nl/documents/product-information/defitelio-epar-product-information_nl.pdf)

norsk (NO) (313.52 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/no/documents/product-information/defitelio-epar-product-information_no.pdf)

polski (PL) (412.17 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/pl/documents/product-information/defitelio-epar-product-information_pl.pdf)

português (PT) (314.46 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/pt/documents/product-information/defitelio-epar-product-information_pt.pdf)

română (RO) (429.97 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/ro/documents/product-information/defitelio-epar-product-information_ro.pdf)

slovenčina (SK) (407.98 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/sk/documents/product-information/defitelio-epar-product-information_sk.pdf)

slovenščina (SL) (384.07 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/sl/documents/product-information/defitelio-epar-product-information_sl.pdf)

Suomi (FI) (313.81 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/fi/documents/product-information/defitelio-epar-product-information_fi.pdf)

svenska (SV) (330.78 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

20/12/2023

[View](/sv/documents/product-information/defitelio-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0063 19/12/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Defitelio : EPAR - All Authorised presentations

English (EN) (20.71 KB - PDF)

**First published:** 25/10/2013

**Last updated:** 25/10/2013

[View](/en/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-478)

български (BG) (41.49 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/bg/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_bg.pdf)

español (ES) (21.24 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/es/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_es.pdf)

čeština (CS) (36.55 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/cs/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (20.97 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/da/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (21.26 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/de/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (20.81 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/et/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (40.17 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/el/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_el.pdf)

français (FR) (21.13 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/fr/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (34.22 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/hr/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (11.21 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/is/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_is.pdf)

italiano (IT) (21.26 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/it/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (38.85 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/lv/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (36.39 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/lt/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (27.33 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/hu/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (37.68 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/mt/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (21.19 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/nl/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (27.14 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/no/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_no.pdf)

polski (PL) (37.36 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/pl/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.12 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/pt/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.42 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/ro/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (35.98 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/sk/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (27.58 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/sl/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (20.84 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/fi/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (21.02 KB - PDF)

**First published:**

25/10/2013

**Last updated:**

25/10/2013

[View](/sv/documents/all-authorised-presentations/defitelio-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Defitelio Active substance defibrotide International non-proprietary name (INN) or common name defibrotide Therapeutic area (MeSH) Hepatic Veno-Occlusive Disease Anatomical therapeutic chemical (ATC) code B01AX01

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

Defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.

It is indicated in adults and in adolescents, children and infants over 1 month of age.

## Authorisation details

EMA product number EMEA/H/C/002393

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

Gentium S.r.l.

Piazza XX Settembre 2

Opinion adopted 25/07/2013 Marketing authorisation issued 18/10/2013 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Defitelio : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (193.45 KB - PDF)

**First published:** 25/09/2014

**Last updated:** 20/12/2023

[View](/en/documents/procedural-steps-after/defitelio-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Defitelio : H/C/002393-II-0056 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/PRAC/273786/2022

English (EN) (5.77 MB - PDF)

**First published:** 09/02/2023

[View](/en/documents/variation-report/defitelio-hc002393-ii-0056-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Defitelio : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/824715/2012

English (EN) (1.66 MB - PDF)

**First published:** 25/10/2013

**Last updated:** 25/10/2013

[View](/en/documents/assessment-report/defitelio-epar-public-assessment-report_en.pdf)

Questions and answers on the positive opinion on the marketing authorisation for Defitelio (defibrotide) - Outcome of re-examination

Reference Number: EMA/457737/2013

English (EN) (78.47 KB - PDF)

**First published:** 26/07/2013

**Last updated:** 26/07/2013

[View](/en/documents/smop-initial/questions-and-answers-positive-opinion-marketing-authorisation-defitelio-defibrotide-outcome-re-examination_en.pdf)

CHMP summary of positive opinion for Defitelio

Adopted

Reference Number: EMA/CHMP/455080/2013

English (EN) (70.03 KB - PDF)

**First published:** 26/07/2013

**Last updated:** 26/07/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-defitelio_en.pdf)

Questions and answers on refusal of the marketing authorisation for Defitelio

Adopted

Reference Number: EMA/167992/2013

English (EN) (75.67 KB - PDF)

**First published:** 22/03/2013

**Last updated:** 22/03/2013

[View](/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-defitelio_en.pdf)

#### News on Defitelio

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 May 2022](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-2-5-may-2022) 06/05/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2013) 26/07/2013

#### More information on Defitelio

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-04-212) on 29 July 2004. Product name was withdrawn from the Community register of orphan medicinal products in October 2023 at the end of the 10-year period of market exclusivity.

#### More information on Defitelio

- [Defitelio - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/defitelio)
- [A National, Post-Registration, Observational Study of the Longterm Safety and Health Outcome of Patients Treated With Defitelio®, Including Patients With Severe Hepatic VOD After HSCT. (DEFIFRANCE Registry) - post-authorisation study](https://catalogues.ema.europa.eu/study/46727)
- [A multi-centre, multinational, prospective observational registry to collect safety and outcome data in patients diagnosed with severe hepatic veno-occlusive disease (VOD) following haematopoietic stem cell transplantation (HSCT) and treated with Defitelio® (DF VOD-2013-03-REG) - post-authorisation study](https://catalogues.ema.europa.eu/study/36318)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/12/2023

## Share this page

[Back to top](#main-content)